
Offen’s Lab of Translational Neuroscience
Felsenstein Medical Research Center
Dept. of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine
Sagol School of Neuroscience
Tel Aviv University

PUBLICATIONS
2010
Benkler C, Offen D, Melamed E, Kupershmidt L, Amit T, Mandel S, Youdim MB, Weinreb O.
EPMA J. 2010 Jun;1(2):343-61. doi: 10.1007/s13167-010-0026-1.
Neurogenesis in the aged and neurodegenerative brain.
Shruster A, Melamed E, Offen D.
Apoptosis. 2010 Nov;15(11):1415-21. doi: 10.1007/s10495-010-0491-y. Review.
Shemesh N, Sadan O, Melamed E, Offen D, Cohen Y.
NMR Biomed. 2010 Feb;23(2):196-206. doi: 10.1002/nbm.1443.
Barhum Y, Gai-Castro S, Bahat-Stromza M, Barzilay R, Melamed E, Offen D.
J Mol Neurosci. 2010 May;41(1):129-37. doi: 10.1007/s12031-009-9302-8.
2009
Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.
Sadan O, Melamed E, Offen D.
Expert Opin Biol Ther. 2009 Dec;9(12):1487-97. doi: 10.1517/14712590903321439. Review.
Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D.
Isr Med Assoc J. 2009 Apr;11(4):201-4.
Barzilay R, Melamed E, Offen D.
Stem Cells. 2009 Oct;27(10):2509-15. doi: 10.1002/stem.172. Review.
Barzilay R, Sadan O, Melamed E, Offen D.
Cytotherapy. 2009;11(4):435-42. doi: 10.1080/14653240902849796.
Grunberg-Etkovitz N, Lev N, Ickowicz D, Avital A, Offen D, Malik Z.
J Environ Pathol Toxicol Oncol. 2009;28(1):5-24.
Barzilay R, Ben-Zur T, Bulvik S, Melamed E, Offen D.
Stem Cells Dev. 2009 May;18(4):591-601. doi: 10.1089/scd.2008.0138.
Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, Ilan AB, Bulvik S, Shemesh N, Krepel D, Cohen Y, Melamed E, Offen D.
Stem Cells Dev. 2009 Oct;18(8):1179-90. doi: 10.1089/scd.2008.0411.
Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D.
J Mol Neurosci. 2009 Sep;39(1-2):199-210. doi: 10.1007/s12031-008-9166-3.
DJ-1 protects against dopamine toxicity.
Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, Offen D.
J Neural Transm (Vienna). 2009 Feb;116(2):151-60. doi: 10.1007/s00702-008-0134-4.
DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS.
Lev N, Ickowicz D, Barhum Y, Melamed E, Offen D.
J Mol Neurosci. 2009 Jun;38(2):94-102. doi: 10.1007/s12031-008-9138-7.
Offen D, Barhum Y, Melamed E, Embacher N, Schindler C, Ransmayr G.
J Mol Neurosci. 2009 Jun;38(2):85-93. doi: 10.1007/s12031-007-9004-z.
2008
Dratviman-Storobinsky O, Hasanreisoglu M, Offen D, Barhum Y, Weinberger D, Goldenberg-Cohen N.
Mol Vis. 2008;14:2171-9.
Sadan O, Shemesh N, Barzilay R, Bahat-Stromza M, Melamed E, Cohen Y, Offen D.
Stem Cells. 2008 Oct;26(10):2542-51. doi: 10.1634/stemcells.2008-0240.
Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D.
Cytotherapy. 2008;10(4):340-52. doi: 10.1080/14653240802021330.
Barzilay R, Kan I, Ben-Zur T, Bulvik S, Melamed E, Offen D.
Stem Cells Dev. 2008 Jun;17(3):547-54. doi: 10.1089/scd.2007.0172.
Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection.
Lev N, Ickowicz D, Melamed E, Offen D.
Neurotoxicology. 2008 May;29(3):397-405. doi: 10.1016/j.neuro.2008.01.007.
2007
Lev N, Melamed E, Offen D.
Handb Clin Neurol. 2007;84:385-98. doi: 10.1016/S0072-9752(07)84050-4.
Offen D, Barhum Y, Levy YS, Burshtein A, Panet H, Cherlow T, Melamed E.
J Neural Transm Suppl. 2007;(72):133-43.
Role of DJ-1 in parkinson's disease.
Lev N, Roncevich D, Ickowicz D, Melamed E, Offen D.
J Mol Neurosci. 2007 Mar;31(3):307.
Bax ablation protects against hepatic ischemia/reperfusion injury in transgenic mice.
Ben-Ari Z, Pappo O, Cheporko Y, Yasovich N, Offen D, Shainberg A, Leshem D, Sulkes J, Vidne BA, Hochhauser E.
Liver Transpl. 2007 Aug;13(8):1181-8.
Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases.
Kan I, Melamed E, Offen D.
Handb Exp Pharmacol. 2007;(180):219-42. Review.
Kan I, Ben-Zur T, Barhum Y, Levy YS, Burstein A, Charlow T, Bulvik S, Melamed E, Offen D.
Neurosci Lett. 2007 May 23;419(1):28-33. Epub 2007 Apr 13.
Bax deficiency reduces infarct size and improves long-term function after myocardial infarction.
Hochhauser E, Cheporko Y, Yasovich N, Pinchas L, Offen D, Barhum Y, Pannet H, Tobar A, Vidne BA, Birk E.
Cell Biochem Biophys. 2007;47(1):11-20.
Kan I, Melamed E, Offen D, Green P.
J Lipid Res. 2007 Mar;48(3):513-7.
Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model.
Grunfeld JF, Barhum Y, Blondheim N, Rabey JM, Melamed E, Offen D.
Exp Neurol. 2007 Mar;204(1):260-3.
2006
Lev N, Ickowicz D, Barhum Y, Blondheim N, Melamed E, Offen D.
Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):1987-95.
Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state.
Gilgun-Sherki Y, Melamed E, Offen D.
Curr Pharm Des. 2006;12(27):3509-19. Review.
Human mesenchymal stem cells express neural genes, suggesting a neural predisposition.
Blondheim NR, Levy YS, Ben-Zur T, Burshtein A, Cherlow T, Kan I, Barzilai R, Bahat-Stromza M, Barhum Y, Bulvik S, Melamed E, Offen D.
Stem Cells Dev. 2006 Apr;15(2):141-64.
Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Lev N, Melamed E, Offen D.
Neurosci Lett. 2006 May 15;399(1-2):27-32. Epub 2006 Apr 11.
Adult stem cells for neuronal repair.
Barzilay R, Levy YS, Melamed E, Offen D.
Isr Med Assoc J. 2006 Jan;8(1):61-6. Review.
Hellmann MA, Panet H, Barhum Y, Melamed E, Offen D.
Neurosci Lett. 2006 Mar 6;395(2):124-8. Epub 2005 Dec 15.
2005
Sadan O, Bahat-Stromza M, Gilgun-Sherki Y, Atlas D, Melamed E, Offen D.
Clin Neuropharmacol. 2005 Nov-Dec;28(6):285-8.
Gilgun-Sherki Y, Barhum Y, Atlas D, Melamed E, Offen D.
J Mol Neurosci. 2005;27(1):125-35.
Therapeutic potential of neurotrophic factors in neurodegenerative diseases.
Levy YS, Gilgun-Sherki Y, Melamed E, Offen D.
BioDrugs. 2005;19(2):97-127. Review.
Bahat-Stroomza M, Gilgun-Sherki Y, Offen D, Panet H, Saada A, Krool-Galron N, Barzilai A, Atlas D, Melamed E.
Eur J Neurosci. 2005 Feb;21(3):637-46.
Integral therapeutic potential of bone marrow mesenchymal stem cells.
Kan I, Melamed E, Offen D.
Curr Drug Targets. 2005 Feb;6(1):31-41. Review.
2004
Elkon H, Melamed E, Offen D.
J Mol Neurosci. 2004;24(3):387-400.
Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.
Levy YS, Stroomza M, Melamed E, Offen D.
J Mol Neurosci. 2004;24(3):353-86. Review.
Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D.
Pharmacogenomics J. 2004;4(5):291-306. Review.
Offen D, Gilgun-Sherki Y, Barhum Y, Benhar M, Grinberg L, Reich R, Melamed E, Atlas D.
J Neurochem. 2004 Jun;89(5):1241-51.
Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice.
Lev N, Barhum Y, Melamed E, Offen D.
Neurosci Lett. 2004 Apr 15;359(3):139-42.
Gilgun-Sherki Y, Melamed E, Offen D.
J Neurol. 2004 Mar;251(3):261-8. Review.
2003
Levy YS, Merims D, Panet H, Barhum Y, Melamed E, Offen D.
J Mol Neurosci. 2003;21(2):121-32.
Gilgun-Sherki Y, Panet H, Melamed E, Offen D.
Brain Res. 2003 Nov 7;989(2):196-204.
Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen D.
Neurosci Res. 2003 Oct;47(2):201-7.
Antioxidant treatment in Alzheimer's disease: current state.
Gilgun-Sherki Y, Melamed E, Offen D.
J Mol Neurosci. 2003;21(1):1-11. Review.
Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D.
Pharmacol Toxicol. 2003 Aug;93(2):66-70.
Gilgun-Sherki Y, Melamed E, Ziv I, Offen D.
Pharmacol Toxicol. 2003 Jul;93(1):54-6.
Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice.
Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub V, Tobar A, Vidne BA.
Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H2351-9.
Apoptosis and Parkinson's disease.
Lev N, Melamed E, Offen D.
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):245-50. Review.
The molecular mechanisms of dopamine toxicity.
Barzilai A, Daily D, Zilkha-Falb R, Ziv I, Offen D, Melamed E, Shirvan A.
Adv Neurol. 2003;91:73-82. Review.
2002
Levy YS, Streifler JY, Panet H, Melamed E, Offen D.
Neurotox Res. 2002 Nov-Dec;4(7-8):609-616.
Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase.
Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D.
J Mol Neurosci. 2002 Jun;18(3):229-38.
Antioxidant therapy in acute central nervous system injury: current state.
Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D.
Pharmacol Rev. 2002 Jun;54(2):271-84. Review.
2001
Elkon H, Melamed E, Offen D.
Cell Mol Neurobiol. 2001 Dec;21(6):771-81.
Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I.
Neurosci Lett. 2001 Dec 28;316(3):129-32.
Gilgun-Sherki Y, Melamed E, Offen D.
Neuropharmacology. 2001 Jun;40(8):959-75. Review.
Panet H, Barzilai A, Daily D, Melamed E, Offen D.
J Neurochem. 2001 Apr;77(2):391-8.
Catechol-O-methyltransferase decreases levodopa toxicity in vitro.
Offen D, Panet H, Galili-Mosberg R, Melamed E.
Clin Neuropharmacol. 2001 Jan-Feb;24(1):27-30.
Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Melamed E, Holmgren A, Barzilai A.
J Biol Chem. 2001 Jun 15;276(24):21618-26.
Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S.
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2837-42.
Molecular biology of dopamine-induced apoptosis : possible implications for Parkinson's disease.
Ziv I, Shirvan A, Offen D, Barzilai A, Melamed E.
Methods Mol Med. 2001;62:73-87. doi: 10.1385/1-59259-142-6:73.